Detalles de la búsqueda
1.
Perioperative Nivolumab and Chemotherapy in Stage III Non-Small-Cell Lung Cancer.
N Engl J Med
; 389(6): 504-513, 2023 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37379158
2.
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
Lancet Oncol
; 23(10): 1274-1286, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108662
3.
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Lancet
; 398(10308): 1344-1357, 2021 10 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34555333
4.
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer.
Br J Cancer
; 125(11): 1561-1569, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34599295
5.
Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 21(11): 1413-1422, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32979984
6.
Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study.
Mycoses
; 62(9): 765-772, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31162731
7.
Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
Clin Transl Oncol
; 2024 Mar 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38530556
8.
Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments.
Curr Opin Oncol
; 25(2): 115-20, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23262832
9.
Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy.
Cancers (Basel)
; 15(24)2023 Dec 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38136333
10.
ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment.
J Immunother Cancer
; 11(9)2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37661097
11.
Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC.
Mol Oncol
; 17(5): 779-791, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36852704
12.
Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients.
Cancers (Basel)
; 15(14)2023 Jul 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37509274
13.
Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1.
J Thorac Oncol
; 18(8): 1055-1069, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37146754
14.
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
J Immunother Cancer
; 10(4)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35477861
15.
Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer.
Front Med (Lausanne)
; 9: 875974, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35707528
16.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
J Clin Oncol
; 40(29): 3383-3393, 2022 10 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35452273
17.
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
J Immunother Cancer
; 10(9)2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36171009
18.
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).
J Clin Oncol
; 40(25): 2924-2933, 2022 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35576508
19.
Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients.
Cancers (Basel)
; 13(13)2021 Jun 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34209601
20.
Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort.
Sci Rep
; 11(1): 21357, 2021 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34725384